The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback